プラダーウィリ症候群治療の世界市場2018-2022

◆英語タイトル:Global Prader-Willi Syndrome Therapeutics Market 2018-2022
◆商品コード:IRTNTR23589
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年11月28日
◆ページ数:102
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、プラダーウィリ症候群治療の世界市場について調査・分析し、市場概要、市場環境、プラダーウィリ症候群治療市場規模、製品別(遺伝子組換え型成長ホルモン、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・プラダーウィリ症候群治療の世界市場概要
・プラダーウィリ症候群治療の世界市場環境
・プラダーウィリ症候群治療の世界市場動向
・プラダーウィリ症候群治療の世界市場規模
・プラダーウィリ症候群治療の世界市場:業界構造分析
・プラダーウィリ症候群治療の世界市場:製品別(遺伝子組換え型成長ホルモン、その他)
・プラダーウィリ症候群治療の世界市場:地域別市場規模・分析
・プラダーウィリ症候群治療の北米市場規模・予測
・プラダーウィリ症候群治療のヨーロッパ・中東・アフリカ市場規模・予測
・プラダーウィリ症候群治療のアジア太平洋市場規模・予測
・プラダーウィリ症候群治療の主要国分析
・プラダーウィリ症候群治療の世界市場:意思決定フレームワーク
・プラダーウィリ症候群治療の世界市場:成長要因、課題
・プラダーウィリ症候群治療の世界市場:競争環境
・プラダーウィリ症候群治療の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Eli Lilly、Novartis、Novo Nordisk、Pfizerなどです。
【レポートの概要】

About this market
The number of pipeline molecules in the global PWS therapeutics market is increasing at a good phase. The pipeline has many promising therapeutics agents, which are expected to boost the market growth. According to industry experts, approximately 15 therapeutics, are under different stages of development in the pipeline. The number of clinical trials is continuously increasing for the development of therapeutics for the treatment of PWS. This is expected to drive them market growth during our forecast period. These increasing number of special drug designations from regulatory bodies is expected to drive the market at a CAGR of close to 5% between 2018-2022.
Market Overview
Special drug designations
PWS is a rare disorder, and its prevalence rate is usually lower compared with other mainstream indications. Therefore, drug manufactures often hesitate to invest large amounts in drug discovery R&D. Therefore, regulatory bodies grant special drug designations, which will help in further development if the drug.
Lack of awareness of PWS
The sales of potential products are difficult to attain due to awareness issues. Though effective treatments available, individual attitudes, beliefs, poor treatment adherence and inadequate communication between clinicians and patients about PWS hinder the market growth.
For the detailed list of factors that will drive and challenge the growth of the Prader Willi syndrome therapeutics market during the 2018-2022, view our report.
Competitive Landscape
This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies. The vendors in the market forming strategic alliances by acquiring businesses gain competitive advantages. The market is formatting alliances between public and private stakeholders. The companies constantly focusing improving their market positions, the competitive environment among the players is quite intense

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Recombinant growth hormones – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by product
• CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strong pipeline
• Increasing strategic alliances
• Use of advanced technologies for diagnosis and treatment of PWS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly and Company
• Novartis
• Novo Nordisk
• Pfizer
PART 15: APPENDIX
• List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global rare disease therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Key clinical trial candidates for treatment of PWS
Exhibit 20: Global PWS therapeutics market by product 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Recombinant growth hormones – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Recombinant growth hormones – Year-over-year growth 2018-2022 (%)
Exhibit 24: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Others – Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global – Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Eli Lilly and Company – Overview
Exhibit 46: Eli Lilly and Company – Business segments
Exhibit 47: Eli Lilly and Company – Organizational developments
Exhibit 48: Eli Lilly and Company – Geographic focus
Exhibit 49: Eli Lilly and Company – Segment focus
Exhibit 50: Eli Lilly and Company – Key offerings
Exhibit 51: Eli Lilly and Company – Key customers
Exhibit 52: Novartis – Overview
Exhibit 53: Novartis – Business segments
Exhibit 54: Novartis – Organizational developments
Exhibit 55: Novartis – Geographic focus
Exhibit 56: Novartis – Segment focus
Exhibit 57: Novartis: Key offerings
Exhibit 58: Novartis – Key customers
Exhibit 59: Novo Nordisk – Overview
Exhibit 60: Novo Nordisk – Business segments
Exhibit 61: Novo Nordisk – Organizational developments
Exhibit 62: Novo Nordisk – Geographic focus
Exhibit 63: Novo Nordisk – Segment focus
Exhibit 64: Novo Nordisk – Key offerings
Exhibit 65: Novo Nordisk – Key customers
Exhibit 66: Pfizer – Overview
Exhibit 67: Pfizer – Business segments
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Pfizer – Key customers



【掲載企業】

Eli Lilly、Novartis、Novo Nordisk、Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[プラダーウィリ症候群治療の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆